Back to Search Start Over

Predictive Value of Vancomycin AUC24/MIC Ratio for 30-day Mortality in Patients with Severe or Complicated Methicillin-Resistant Staphylococcus aureus Infections: A Multicenter Retrospective Study.

Authors :
Hanai, Yuki
Hashi, Hideki
Hanawa, Kazumi
Endo, Aiju
Miyazaki, Taito
Yamaguchi, Tetsuo
Harada, Sohei
Yokoo, Takuya
Uekusa, Shusuke
Namiki, Takaya
Yokoyama, Yoshiaki
Asakawa, Daiki
Isoda, Ryo
Enoki, Yuki
Taguchi, Kazuaki
Matsumoto, Kazuaki
Matsuo, Kazuhiro
Source :
Pharmaceutical Research. Jul2024, Vol. 41 Issue 7, p1381-1389. 9p.
Publication Year :
2024

Abstract

Background: Although vancomycin is typically employed against methicillin-resistant Staphylococcus aureus (MRSA) infections, the optimal ratio of 24-h area under the concentration–time curve to minimum inhibitory concentration (AUC24/MIC) for severe or complicated infections lacks clear guideline recommendations. This study aimed to determine the target AUC24/MIC ratio associated with treatment outcomes of infections treated with vancomycin. Methods: This retrospective multicenter cohort study included adult patients receiving ≥ 5 days of vancomycin for severe/complicated MRSA infections (e.g., osteoarticular, pulmonary, endocarditis, etc.) between January 2018 and December 2023. The primary outcome was 30-day mortality, with secondary outcomes including clinical success, microbiological eradication, and nephrotoxicity. Receiver operating characteristic (ROC) curve analysis was used to identify the AUC24/MIC cutoff for 30-day mortality. Multivariate regression analysis was used to determine association between AUC24/MIC and outcomes. Results: This study included 82 patients. ROC identified a target AUC24/MIC of ≥ 505 for 30-day mortality. The overall 30-day mortality rate (22.0%) was significantly higher for below average AUC24/MIC cutoff (34.1%) than for above AUC24/MIC cutoff group (9.8%). Multivariate analysis confirmed AUC24/MIC of < 505 as an independent predictor (adjusted odds ratio, 5.001; 95% confidence interval, 1.335–18.75). The clinical success rate differed significantly between below- and above-cutoff groups, whereas microbiological eradication tended to favor the above-cutoff group. The nephrotoxicity rates were comparable between groups. Conclusions: In treating severe/complicated MRSA infections, vancomycin AUC24/MIC ratio ≥ 505 was independently associated with favorable 30-day mortality. Given the retrospective nature of this study, further prospective studies are essential to confirm the reliability of the target AUC24/MIC ratios. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07248741
Volume :
41
Issue :
7
Database :
Academic Search Index
Journal :
Pharmaceutical Research
Publication Type :
Academic Journal
Accession number :
179459792
Full Text :
https://doi.org/10.1007/s11095-024-03728-9